Literature DB >> 19320656

Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample.

M L Mostacciuolo1, E Pastorello, G Vazza, M Miorin, C Angelini, G Tomelleri, G Galluzzi, C P Trevisan.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with a partial deletion on chromosome 4q35. Few relevant investigations have been reported on its epidemiology and were essentially based on clinical diagnosis, having been performed before recognition of the molecular mutation. We report an epidemiological survey on FSHD patients, in which the diagnosis was obtained by combined clinical and molecular evaluation. The survey concerned the north-east Italian province of Padova, an area of 871,190 inhabitants (1 January 2004). We identified 40 patients affected by FSHD based on clinical diagnosis. In 33 of them, the EcoRI fragment size in the 4q35 region ranged from 14 to 35 kb. Four other patients belonging to the same family harbored a 38-kb fragment. In these four cases, the relationship between the borderline deletion with the mild FSHD phenotype was corroborated by additional haplotype reconstruction and segregation analysis. Interestingly, the same mild facial-sparing clinical pattern was apparent only in one other patient with an EcoRI fragment of 32 kb, suggesting that this unusual FSHD phenotype may be due to very small 4q35 deletions. On the whole, estimating a prevalence rate of 44 x 10(-6), our survey confirmed FSHD as one of the most frequent neuromuscular disorders in Western populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320656     DOI: 10.1111/j.1399-0004.2009.01158.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  58 in total

1.  Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.

Authors:  Mirjam Larsen; Simone Rost; Nady El Hajj; Andreas Ferbert; Marcus Deschauer; Maggie C Walter; Benedikt Schoser; Pawel Tacik; Wolfram Kress; Clemens R Müller
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

2.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

3.  Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers.

Authors:  Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

4.  Restrictive lung involvement in facioscapulohumeral muscular dystrophy.

Authors:  Michele A Scully; Katy J Eichinger; Colleen M Donlin-Smith; Rabi Tawil; Jeffery M Statland
Journal:  Muscle Nerve       Date:  2014-09-29       Impact factor: 3.217

Review 5.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

6.  Reachable workspace reflects dynamometer-measured upper extremity strength in facioscapulohumeral muscular dystrophy.

Authors:  Jay J Han; Evan De Bie; Alina Nicorici; Richard T Abresch; Ruzena Bajcsy; Gregorij Kurillo
Journal:  Muscle Nerve       Date:  2015-06-19       Impact factor: 3.217

7.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

8.  Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Authors:  Nicholas E Johnson; Christine Quinn; Eileen Eastwood; Rabi Tawil; Chad R Heatwole
Journal:  Muscle Nerve       Date:  2012-12       Impact factor: 3.217

Review 9.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

Review 10.  Facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey Statland; Rabi Tawil
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.